Next Gen Immuno-Oncology Congress The next step towards changing treatment paradigms in immuno-oncology 13 th - 14 th March 2017, London Heathrow Marriott Hotel, London UK Next Gen Immuno-Oncology Congress The next step towards changing treatment paradigms in immuno-oncology 13 th - 14 th March 2017, London Heathrow Marriott Hotel, London UK Synopsis: The Next Gen Immuno-Oncology Congress 2017 took place in London, UK on 13th and 14th March 2017 with an aim to provide a platform to discuss Antibody drug conjugates, Bispecific antibodies, immune checkpoint blockade and brain storming about the immuno-oncology technologies available and its advances. This conference witnessed participation from experts from pharma and academia who shared their latest research with respect to rapidly advancing immuno-oncology technologies in focus preclinical and clinical development of first and second generation of therapeutics using different molecules and immune system that include Antibody drug conjugates, bispecific antibodies, immune checkpoint blockades, adoptive cellular therapy. It offered a unique insight into the advancement of technologies and also helped attendees determine the best technology for their research. The conference offered 2 days of effective networking with leading manufacturers, distributors and service providers of immuno-oncology and antibody based therapies. Recommended by MARKETSANDMARKETS
Transcript
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology13th
- 14th March 2017, London Heathrow Marriott Hotel, London UK
Synopsis:
The Next Gen Immuno-Oncology Congress 2017 took place in London, UK on 13th and 14th March 2017 with an aim to provide
a platform to discuss Antibody drug conjugates, Bispecific antibodies, immune checkpoint blockade and brain storming about
the immuno-oncology technologies available and its advances. This conference witnessed participation from experts from
pharma and academia who shared their latest research with respect to rapidly advancing immuno-oncology technologies in
focus preclinical and clinical development of first and second generation of therapeutics using different molecules and immune
system that include Antibody drug conjugates, bispecific antibodies, immune checkpoint blockades, adoptive cellular therapy.
It offered a unique insight into the advancement of technologies and also helped attendees determine the best technology
for their research. The conference offered 2 days of effective networking with leading manufacturers, distributors and service
providers of immuno-oncology and antibody based therapies.
Recommended by
MARKETSANDMARKETS
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Bispecific Antibodies:
A case study was presented by Lolke de Haan, Senior Director, Toxicology, Global Cancer Immunotherapy Safety Lead MedImmune, Cambridge, UK on “Challenges in the nonclinical development of mAb-based cancer immunotherapy Products”.
Another case study presented on “A versatile modular platform, BiXAb®, for the development of bispecific antibodies” by chairman and scientific advisor, Eugene ZHUKOVSKY, CSO, Biomunex Pharmaceuticals, France.
Roland Kontermann, Professor and Deputy Director, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart, Germany, one of the leading researcher in the field presented on “Development of bispecific antibodies for cancer therapy”.
Immune checkpoint inhibitors:
A case study was presented by Sonia Quaratino, Global Clinical Program Leader at Novartis, Switzerland on “Combination strategies for checkpoint inhibitors”.
Another case study presented on “IgA as novel isotype for the treatment of cancer” by our chairman Jeanette Leusen, Associate professor and Head, Immunotherapy group, Laboratory Translational Immunology, University Medical Centre Utrecht, The Netherlands
Key note presentation on “PD-1 antibody, a broad spectrum antineoplastic therapy, has the potential to transform cancer care” by Roy Baynes, Senior Vice President and Head, Global Clinical Development, Chief Medical Officer, Merck Sharp & Dohme, USA
Antibody Drug conjugates:
Lioudmila Tchistiakova, Senior Director of Global Bio therapeutic Technologies from Pfizer BioTx, Maryland USA one of the leading researchers in the field presented on “Antibody drug conjugates development platform at Pfizer”.
A case study was presented by Yvonne Andersson, Scientist and Project leader, Anti-cancer therapy with immunotoxin from Oslo University Hospital, Norway on “Phase I Studies with MOC31PE Immunotoxin Targeting EpCAM”
The presentation on “MEDI1873, a novel hexameric human GITR agonist which drives antitumour immune response” presented by Maria Groves, Head of CRUK-MEDI-Alliance Laboratory, MedImmune, UK
Event Highlights:
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Silver Sponsor:
Sponsor/Exhibitor:
Gold Sponsor:
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Media Partners:
Supporting Associations:
Endorsed
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Expert Speaker Panel:
Andre FrenzelSenior antibody engineering expert, Institute of Biochemistry, Biotechnology & Bioinformatics, Technical University of Braunschweig, Germany
Nicolas FischerHead, ResearchNovimmune, Switzerland
Hardev PandhaProfessor, Medical Oncology- Tumour ImmunologyUniversity of Surrey, UK
Sophia N. KaragiannisReader, Translational Cancer Immunology, Head, Cancer Antibody Discovery and ImmunotherapyKings College London, UK
Christophe HenryProject Lead, Translational Medicine Sanofi, France
Thomas ValeriusMedical Department II , Section on Stem Cell and Immunotherapy University Hospital Schleswig – Kiel University, Germany
Christoph SachseSite Head Berlin, NMI TT PharmaservicesNatural Sciences and Medical Institute at the University of Tübingen, Germany
Richard O’ KennedyProfessor, Biosciences- School of BiotechnologyDublin City University, Dublin, Ireland
Lindy Durrant Professor, Cancer Immunotherapy, Health Sciences Academic Clinical OncologyThe University of Nottingham, UK
Helmout ModjtahediProfessor, Cancer Biology and Cancer Theme DirectorKingston University London, UK
Matthias FriedrichDirector, Nonclinical developmentAMGEN Research (Munich) GmbH, Germany
Eugene Zhukovsky Chief Scientific OfficerBiomunex Pharmaceuticals, France
Randolf KerschbaumerDirector R&D, Antibody Technology Shire, Austria
Darren SchofieldSenior Research Scientist MedImmune Ltd, UK
Robert HawkinsDirector and Professor, Medical OncologyUniversity of Manchester and Christie Hospital, UK
Mahendra DeonarainChief Science and Operating OfficerAntikor Biopharma Ltd, UK
Benjamin E. WillcoxProfessor of Molecular Immunology, Director-Cancer Immunology and Immunotherapy CentreUniversity of Birmingham, UK
Mark Creighton-GutteridgeHead, Discovery and New Technologies, Oncology Cell Therapy UnitGlaxoSmithKline, UK
A. Graham PockleyDirector and Professor, ImmunobiologyNottingham Trent University, UK
Martina SeiffertTeam Leader, CLL Tumor MicroenvironmentGerman Cancer Research Centre, Germany
Chris AllenSr. Field Application SpecialistThermo Fisher Scientific, UK
Marlon J. HinnerDirector, Immuno-Oncology Pieris Pharmaceuticals, Germany
Maxim ShevtsovProfessor, Immunotherapy Group, Klinikum rechts der Isar Technische Universität München, Germany
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Maria GrovesHead, CRUK-MEDI Alliance LaboratoryMedImmune, UK
Angus DalgleishProfessor and Chair, Institute of Infection and ImmunitySt. George’s University of London, UK
Sonia QuaratinoGlobal Clinical Program LeaderNovartis, Switzerland
Christine Schuberth-WagnerSenior Vice President ResearchRigontec GmbH, Germany
Thierry WurchDirector, External Research & Innovation in in Immuno-oncology, Therapeutic Innovation Pole in Oncology Institute of Recherché Servier, France
Alessandra CesanoChief Medical OfficerNanoString Technologies
Nathalie FayeMedical DirectorMedian Technologies
Martin SchwillPhd, Department of Biochemistry-Laboratory of A. PlueckthunUniversity of Zurich, Switzerland
Craig MalcolmStrategic Collaborations ManagerPromega UK Ltd, UK
Ivan Diaz PadillaGlobal Clinical Leader Global Drug Development, OncologyNovartis Pharma AG, Switzerland
Jens LohrmannSenior Global Program Manager, Translational Clinical OncologyNovartis, Switzerland
Roland KontermannProfessor and Deputy Director, Biomedical Engineering , Institute of Cell Biology & ImmunologyUniversity of Stuttgart, Germany
Sine Reker HadrupAssociate Professor and section Head, Immunology and VaccinologyTechnical University of Denmark, Denmark
Steve AndertonChief Scientific OfficerAquila BioMedical, UK
Andrew ThorleyLecturer, National Heart and Lung InstituteImperial College London, UK
Ahuva NissimReader, Antibody and Therapeutic Engineering Biochemical Pharmacology, Barts and The London, Queen Mary’s School of Medicine and Dentistry, John Vane Science Centre, UK
Lioudmila TchistiakovaSenior Director, Global Biotherapeutic TechnologiesPfizer BioTx, USA
Matthew BakerVP Immunology & OncologyCelentyx Ltd,UK
Yvonne AnderssonScientist and Project leader, Anti-cancer therapy with immunotoxinOslo University Hospital., Norway
Lolke de HaanSenior Director, Toxicology, Global Cancer Immunotherapy Safety Lead, MedImmune, Cambridge, UK
Charles DumontetAdjunct Director , Cancer Research Center of Lyon, Chair, Research Council of the Hospices Civils de Lyon, Cancer Research Center of Lyon, France
Roy BaynesSenior Vice President and Head, Global Clinical Development, Chief Medical OfficerMerck Sharp & Dohme, USA
Jeanette LeusenAssociate professor and Head, Immunotherapy group Laboratory Translational ImmunologyUniversity Medical Centre Utrecht, The Netherlands
Payal RoychoudhuryField Applications ScientistMaxcyte, Maryland USA
Carsten CorveyGroup Leader, Global Bio therapeuticsSanofi, Germany
Christian OstheimerRadiation Oncology, Martin Luther University Halle-Wittenberg, Germany
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Antibody drug conjugates Bispecific Antibodies Immune checkpoint inhibitors• ADCs development Preclinical and
Translational Oncology
• Oncology
• Clinical development
• R&D- Discovery and process
• PKPD/ADME/Tox
• Antibody Engineering
• Antibody therapeutics
• Physio-Chemistry /Synthetic Chemistry and/ Bio
conjugation
• Bi-specifics- Preclinical and Translational Oncology
• Oncology
• Clinical development
• R&D- discovery and process
• Discovery
• Target Validation
• Bioanalysis
• Therapeutic areas
• PKPD/ADME/Tox
• Biologics -antibody
• Cancer immunotherapy• Immune checkpoint
targets• Checkpoint inhibition• Cellular therapy• Clinical research• Combination therapy• Cancer Vaccines• Preclinical and
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Testimonials
“The topics and the speakers were very good, and even it was so good parallel presentations that I wish to be in two rooms at the same time. The panel discussions were excellent – learned a lot. I also think it was a good idea to have it on an airport hotel, making it easier to get in contact with people and not everyone disappeared to other places. I really looking forward to your next conference on the same topics”
Yvonne AnderssonScientist and Project leader, Anti-cancer therapy with immunotoxin
Oslo University Hospital, Norway.
“I found the meeting very interesting with the parallel sessions on bispecifics, ADCs and ICIs. I wish I could have duplicated my-self to listen to more presentations.”
Charles DumontetAdjunct Director, Cancer Research Center of Lyon,
Chair of the Research Council of the Hospices Civils de LyonCancer Research Center of Lyon, France
“It was a pleasure to meet you and allow me to congratulate you and the organizing committee for the success of the meeting. I think it went quite well and, compared to other B2B meetings that I have attended, this ranks high, not only in terms of organization/logistics, but also in terms of scientific content”
Ivan Diaz-Padilla MD, PhD, Medical Director
Global Drug Development (Oncology), Novartis Pharma AG
“Next Gen ImmunoOncology brought together translational scientists from a range of disciplines and across industry and academia. We enjoyed discussing innovative insights and sharing experiences and ideas with many colleagues. Thank you very much for putting together an excellent agenda.”
Dr. Sophia N. KaragiannisReader in Translational Cancer Immunology,
Head of Cancer Antibody Discovery and Immunotherapy St. John’s Institute of Dermatology, King’s College London
“Thank you very much for organizing this interesting meeting. The location, organization and service before and during the meeting was exceptionally good”
Martina SeiffertTeam Leader, CLL Tumor MicroenvironmentGerman Cancer Research Centre, Germany
”It was a pleasure to meet you also! And the conference indeed turned out to be excellent! I heard a lot of great feedback and the attendees were very impressed with the quality of the speakers and topics covered.”
Eugene ZhukovskyChief Scientific Officer
BIOMUNEX Pharmaceuticals, France
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
Testimonials
“The conference was very well organized with a lot of interesting topics and excellent speakers. I really enjoyed it and had a lot of fruitful discussions with several attendees.”
Matthias FriedrichDirector, Nonclinical development
AMGEN Research (Munich) GmbH, Germany
“I wanted to thank you for the well organized meeting and the inspiring atmosphere. I really made good contacts there”
Christine Schuberth-WagnerSenior Vice President Research
Rigontec GmbH, Germany
“Thank you very much for the opportunity to actively participate in this meeting. I very much enjoyed the conference, as you’ve certainly put together a highly interesting and relevant program “
Dr. Christoph SachseSite Head Berlin
NMI TT Pharmaservices
“The meeting provided an excellent insight in current hot topics in immuno-oncologic research. The presentations were both interesting and scientifically stimulating. The venue was excellent to ensure a close scientific person-to person exchange and sharing of ideas”
Dr. med. Christian OstheimerClinic and Polyclinic for radiotherapy
University Hospital Halle
“The congress on Immuno-Oncology covered very many key areas of interest to both researchers and industry. The lectures were well prepared and there were lots of opportunities for questions and discussions during the meeting.”
Richard O’ KennedyProfessor, Biosciences- School of Biotechnology
Dublin City University, Ireland
“The conference was excellent and I enjoyed meeting so many people leading in the field.”Martin Schwill
Phd, Department of Biochemistry-Laboratory of Prof. A. PlueckthunUniversity of Zurich, Germany
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
• Abzena• ACEA Biosciences• ADC Therapeutics• Amgen Limited• Amgen Research (Munich) GmbH• Antibodies — Open Access Journal• Antibody• Antikor Biopharma Ltd• Aquila Biomedical Ltd• School of Medicine and Dentistry• Bentham Science• Bicycle Therapeutics• BIOMUNEX Pharmaceuticals• Biosceptre International• BliNK Biomedical SAS• BTX• Cancer Drug Development Forum (CDDF)• Cancer Research Center of Lyon, • Capella Bioscience• Cardiff University• Celentyx Ltd• Celgene Ltd• Centauri Therapeutics Limited• Compugen Ltd• Crescendo Biologics • Cristal Therapeutics• Cyclogenix Ltd• Department of Immunology Tübingen • Martin Luther Univ• DomainX• Drug Target Review• Dublin City University• Erasmus Medical center, Rotterdam• F-star Biotechnology Ltd• GEN Magazine• German Cancer Research Center• Gleneagles Kota Kinabalu• GSK• HISTALIM• Horizon Discovery• ImmuMap Services• Imperial College London• Incyte Biosciences UK Ltd• INOVOTION• Iomet Pharma• Nottingham Trent University
• Karolinska Institutet• Karus Therapeutics Limited• Kelle University• King’s College London• Kingston University• Kingston University London• Klinikum rechts der Isar • Technische Universität München• Kymab• Kymab Ltd• Lonza Cologne GmbH• Ludwig Center for Cancer Research of the
University of Lausanne• MaxCyte• Maxivax Sa• MEDIAN Technologies• MedImmune• Medway NHS Foundation Trust• Merck Group (EMD Serono)• Merck KGaA• Merck Sharp & Dohme• Mironid Limited• Modern Biosciences Plc• Momenta Pharmaceuticals• MRC Technology• MyCartis NV• NanoString Technologies• Nebion AG• NETRIS Pharma• NIBR Oncology• Norut Northern Research Institute• Novartis Pharma AG• Novartis Switzerland• Novimmune• Oblique Therapeutics• OCTIMET Oncology NV• OGD2 Pharma• OracleBio• Oslo University Hospital• Oxford Biotherapeutics• PerkinElmer• Peter MacCallum Cancer Institute• Pfizer• Pieris Pharmaceuticals• Plymouth University• Promega UK Ltd
• ProQinase GmbH• ProteoGenix• Queen Mary University• Rigontec GmbH• Royal College of Surgeons in Ireland• Royal Holloway University of London• Sanofi• Sci Doc Publishers• Servier• Shire• Spirogen Medimmune• St. George’s University of London, UK• Syndivia SAS• Synthon Biopharmaceuticals B.V. • Technical University of Denmark, • Technische Universitat Darmstadt• Thermo Fisher Scientific• T-Rex Publishing• TU Braunschweig• Tusk Therapeutics Ltd• UCL Institute for Liver and Digestive
Health• UMC Utrecht• Univeristy Hospital Basel• Univeristy of Birmingham• University Hospital Basel• University Hospital of Zurich• University Hospital Schleswig• University Medical Center Groningen• University Medical Centre Hamburg Ep-
pendorf• University Medical Centre Utrecht• University of Birmingham, • University of Manchester and Christie
Hospital• University of Nottingham• University of Southampton• University of Stuttgart• University of Surrey, UK• University of Sussex• University of Turin• University of Zurich• Vaccibody AS• Vrije Universiteit Brusse
Attendees 2017
Next Gen
Immuno-Oncology CongressThe next step towards changing treatment paradigms in immuno-oncology
13th - 14th March 2017, London Heathrow Marriott Hotel, London UK
MarketsandMarkets Events is a wholly owned division of MarketsandMarkets, a global market research and intelligence company producing over 1200 premium market research reports every year across 12 different industry verticals. By bringing together expert speakers from across the world and leading technology and service providers, Events provide a senior level educational and networking platform where knowledge is shared and partnerships and collaborations can be formed.
With offices in Asia, Europe and USA MarketsandMarkets ensures a truly global attendance at every event where attendees, speakers, exhibitors and sponsors can exchange ideas in a relaxed and professional environment.
About MarketsandMarkets:
Submitting Paper Proposal:You can submit your paper proposal on any of the event topics, which will be available on the events website shortly.
In 2016, the event will be expanding its exhibition area and will offer an opportunity for exhibiting and showcasing your latest technologies, services, and products. We offer tailor made packages to sponsor the event based on your marketing budget.Contact: Abhinay Roy | Senior Sponsorship Manager
We actively collaborate with publications, online portals and not-for-profit associations. To know more write to us.E: [email protected] | T: +91 20 3010 8270
![Tumor Mutational Burden Immuno-Oncology Scientific Updates · Title: Tumor Mutational Burden Immuno-Oncology Scientific Updates Author: Ritterhouse, Lauren [BSD] - PTH Created Date:](https://static.documents.pub/doc/80x56/5fc25b7302cd4e75fc4563dd/tumor-mutational-burden-immuno-oncology-scientific-updates-title-tumor-mutational.jpg)
